Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Harvard Business School
McKinsey
Mallinckrodt
McKesson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,439,241

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,439,241
Title:Compounds, formulations, and methods for treating or preventing rosacea
Abstract: In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.
Inventor(s): DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee: Galderma Laboratories, Inc. (Fort Worth, TX)
Application Number:10/853,585
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,439,241
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,439,241

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes   Start Trial   Start Trial TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,439,241

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 530185   Start Trial
Australia 2004242967   Start Trial
Australia 2005247467   Start Trial
Australia 2011231543   Start Trial
Brazil 112012024289   Start Trial
Brazil PI0511519   Start Trial
Canada 2530938   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
McKesson
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.